Description
Retatrutide 10 mg Dual-chamber cartridge in Europe | LIFE supplies Retatrutide in a dual-chamber research format containing 10 mg of lyophilised peptide and a separately stored diluent. After activation, the cartridge provides a final volume of 1 mL.
Retatrutide in dual-chamber format
Retatrutide is an investigational triple-agonist peptide that combines activity at three metabolic receptor systems:
- GLP-1 receptor
- GIP receptor
- glucagon receptor
This makes Retatrutide mechanistically broader than single GLP-1 agonists such as Semaglutide and dual GLP-1/GIP agonists such as Tirzepatide. Its triple-receptor profile has made Retatrutide one of the most closely followed compounds in current metabolic research, particularly in studies of body-weight regulation, appetite signalling, glucose metabolism and energy balance.
The dual-chamber version contains the same Retatrutide research compound as our conventional vial, but uses a different preparation format. Instead of supplying the lyophilised peptide in a vial and the diluent separately, both components are housed within one cartridge while remaining physically separated until activation.
This provides the convenience of an integrated cartridge without transporting or storing Retatrutide as a premixed peptide solution.
Lyophilized during transportation
Peptides are generally less stable after they have been dissolved. Premixed solutions begin their post-reconstitution stability period before reaching the researcher and are affected by ambience temperature and mechanical stress even with claimed cold-chain shipping within hours.
The dual-chamber cartridge keeps Retatrutide lyophilized and physically separated from the liquid diluent until activation. This retains the main transport advantage of a conventional freeze-dried vial while integrating both components into one cartridge. The cartridge should still be protected from excessive heat. Refrigerated storage at 2–8°C is recommended for long-term storage.
Read more on the differences between a dual-chamber cartridge and the common pen peptide in our article Dual-chamber peptide cartridges: how the system works.
Simplified preparation
A conventional vial requires a separate diluent, volume calculation and liquid transfer. The dual-chamber cartridge contains a predetermined diluent volume and allows the two components to combine inside the cartridge.
This reduces separate preparation steps and the possibility of:
- selecting the wrong diluent volume;
- losing material during transfer;
- excessive agitation or foaming;
- contamination during handling;
- producing an unintended final concentration.
A specifically compatible reusable device is required for activation. Compatibility with conventional insulin pens should not be assumed.
Concentration: 10 mg in 1 ml
After activation, the cartridge contains 10 mg Retatrutide in a final volume of 1 ml:
10 mg ÷ 1 ml = 10 mg/ml
This is twice the concentration of a conventional 10 mg vial prepared with 2 ml.
| Preparation | Concentration | Quantity in 0.1 mL |
| 10 mg in 1 mL | 10 mg/mL | 1 mg |
| 10 mg in 2 mL | 5 mg/mL | 0.5 mg |
Calculations prepared for a 2 ml solution cannot be applied directly to the cartridge. For the same research quantity, the required liquid volume from the 1 ml cartridge is half as large.
Important
The cartridge is not supplied as a premixed peptide solution. It is intended strictly for laboratory and analytical research and is not intended for human or veterinary use.
Research context
Retatrutide is designed to activate GLP-1, GIP and glucagon receptors simultaneously.
- GLP-1 signalling is associated with appetite regulation, gastric emptying and glucose-dependent insulin secretion.
- GIP signalling contributes to incretin activity, insulin secretion and nutrient metabolism.
- Glucagon receptor activity differentiates Retatrutide from Semaglutide and Tirzepatide and is being investigated for its potential role in energy expenditure and broader metabolic regulation.
This combination has produced substantial interest in Retatrutide as a next-generation metabolic research compound.
Product characteristics
Compound: Retatrutide
Quantity: 10 mg
Format: Dual-chamber research cartridge
Peptide state before activation: Lyophilised
Final volume after activation: 1 mL
Final concentration: 10 mg/mL
Application: Laboratory and analytical research
Compatible device: Requires a compatible reusable dual-chamber device
The peptide and diluent remain physically separated within the cartridge until activation.
The cartridge is not supplied as a premixed Retatrutide solution.
Retatrutide vial or dual-chamber cartridge?
Both formats contain Retatrutide for laboratory research. The principal difference is how the peptide and diluent are supplied.
Standard Retatrutide vial
The peptide is supplied as a conventional lyophilised powder in a sealed vial. Diluent is obtained separately and the required volume must be transferred into the vial during laboratory preparation.
Retatrutide dual-chamber cartridge
The lyophilised peptide and a predetermined volume of diluent are contained in separate chambers of the same cartridge. They remain separated during storage and transportation and are combined only when the cartridge is activated.
The dual-chamber format therefore retains the principal stability advantage of transporting Retatrutide in lyophilised form while reducing the number of separate components and preparation steps required.
Researchers who prefer conventional laboratory preparation can choose our Retatrutide 10 mg vial.
Frequently Asked Questions
What does the Retatrutide dual-chamber cartridge contain?
Each cartridge contains 10 mg of lyophilised Retatrutide and a separately contained diluent. The two components remain physically separated until activation.
Is the Retatrutide already mixed with liquid?
No. Retatrutide remains lyophilised during storage and transportation. The liquid is held in a separate chamber and only contacts the peptide when the cartridge is activated.
What is the final concentration?
After activation, 10 mg of Retatrutide is contained in a final volume of 1 mL, giving a concentration of 10 mg/mL.
Is this the same Retatrutide as the standard vial?
Yes. The distinction is the presentation and preparation format. The standard product supplies Retatrutide in a conventional vial, while this product uses a dual-chamber cartridge.
Does the cartridge fit a standard insulin pen?
Compatibility with conventional insulin pens should not be assumed. The cartridge requires a specifically compatible reusable dual-chamber device.
Why use a dual-chamber cartridge instead of a premixed cartridge?
The peptide remains freeze-dried until activation. Peptides are generally more stable in lyophilised form than after reconstitution, making it preferable to keep the peptide and liquid separated during storage and transportation.
Where can I find detailed Retatrutide research information?
Our standard Retatrutide 10 mg page contains the full research overview, including receptor activity, published clinical findings, safety and tolerability findings, research dosing schedules, comparisons with Semaglutide and Tirzepatide, and published references.
Is this product intended for human use?
No. This product is supplied strictly for laboratory and analytical research and is not intended for human or veterinary use.
Related research
For detailed information about the compound itself, see Retatrutide 10 mg, including published clinical research, mechanism of action and research references.
Researchers comparing metabolic compounds may also examine:
Tirzepatide
Semaglutide
Cagrilintide
Cagrilintide + Retatrutide
Browse our Metabolic research collection or the complete Dual-chamber cartridge range.
NOTE: This information is provided for educational and research reference only and does not constitute medical advice.
Disclaimer: This product is sold for research purposes only. It is not intended to diagnose, treat, cure or prevent any disease. Buyer assumes full responsibility for proper handling and use.
